Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
More toxic chemo = more biological aging. A new simulation study in JAMA Network Open found that breast cancer survivors treated with anthracyclines — a more cytotoxic chemotherapy — lost a projected median of 9.4 life-years due to biological age acceleration. The effect was strongest in younger women and grew more pronounced over time, raising important questions about long-term survivorship care.
A new simulation study published in JAMA Network Open suggests that more cytotoxic breast cancer chemotherapy doesn't just fight cancer — it may also accelerate biological aging in ways that significantly shorten survivors' lives. Researchers used a validated breast cancer model from the Cancer Intervention and Surveillance Modeling Network, integrating data on biological aging (measured via the p16INK4a cellular senescence biomarker) and breast cancer epidemiology across a simulated population of 400 million U.S. women.
The findings showed that women treated with anthracycline-based (more cytotoxic) regimens faced substantially worse long-term outcomes compared to those on less cytotoxic, non-anthracycline protocols — and the gap widened considerably over time. Younger survivors, particularly those diagnosed between ages 30–39, were hit hardest.
By the Numbers:
Why it matters: As breast cancer survival rates improve, what happens after treatment matters more than ever. These findings suggest survivorship care guidelines may need to account for biological age — not just chronological age — to better protect long-term health outcomes for the millions of women living beyond a breast cancer diagnosis.